Small Cap Stocks To Watch - HALO, DNDN, USAT
Sep 27, 2013 (M2 PRESSWIRE via COMTEX) --
Halozyme Therapeutics (Nasdaq: HALO) $10.57. Today announced that the commercial launch of Herceptin SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. This time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) received marketing authorization from the European Commission on August 28, 2013 for the treatment of patients with HER2-positive breast cancer and was launched upon approval.
Herceptin SC reduces treatment times and enhances convenience compared to the standard intravenous (IV) form.
"With pricing on par with the intravenous formulation, Herceptin SC represents a compelling treatment alternative for breast cancer patients in Europe, and we congratulate Roche on making this time-saving therapy available to patients in Europe so quickly," said Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme. "This will be the third commercial product using our rHuPH20 enzyme and represents a significant achievement for our technology and company as a whole."
What They Do: Halozyme Therapeuticsis a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care.
Dendreon Corporation (Nasdaq: DNDN) $2.98. Today announced the presentation of data from clinical studies featuring PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for metastatic castrate-resistant prostate cancer (mCRPC), at the 2013 European Cancer Congress in Amsterdam, September 27-October 1, 2013.
Preliminary Phase II data surrounding DN24-02, an investigational autologous cellular immunotherapy for patients with surgically resected HER2+ urothelial cancer, will also be presented.Preliminary data from a Phase II combination study demonstrated that PROVENGE product potency and immunological prime-boost responses are maintained when administered concurrently or sequentially with abiraterone acetate (AA) plus prednisone.
Additionally, preliminary data from an ongoing open-label study of PROVENGE treatment in men with mCRPC who were previously treated with PROVENGE in the androgen dependent prostate cancer (ADPC) setting suggest long-lived immunological memory to PROVENGE years following initial treatment.
"The data presented at this Congress surrounding PROVENGE and DN24-02 further our understanding of the potential benefits of these personalized immunotherapies," said Mark Frohlich, M.D., executive vice president of research and development and chief medical officer at Dendreon. "The ability to sequence treatments such as PROVENGE with other therapies has the potential to transform the treatment of advanced prostate cancer, particularly in the current oncology landscape with the encouraging results from immunotherapy combination regimens."
What They Do: Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics.
USA Technologies (Nasdaq: USAT) $1.90. Today reported results for the fourth quarter and full fiscal year ended June 30, 2013.Fiscal 2013 financial highlights, compared to the prior year, included: 29% increase in license and transaction fee revenues to $30.0 million, representing 84% of total revenues for the 2013 fiscal year; 24% increase in total revenues to $35.9 million; Adjusted EBITDA of $5.8 million up from an Adjusted EBITDA loss of ($2.8) million; GAAP net income of $0.9 million from a GAAP net loss of ($5.2) million.
Non-GAAP net income of $0.9 million, up from a non-GAAP net loss of ($3.8) million (fiscal 2013 excludes $0.3 million of Other income for change in fair value of warrants and $0.3 million in proxy expenses and fiscal 2012 excludes $1.8 million Other income for change in fair value of warrants and $3.2 million in proxy and separation expenses).
Cash generated from operations was $6.0 million for fiscal 2013 compared to $0.08 million for fiscal 2012, an increase due primarily to substantial improvements in operating performance over the course of fiscal 2013 when compared to 2012. Cash and cash equivalents stood at approximately $6.0 million as of June 30, 2013.
What They Do: USA Technologies is a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries.
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com.
[ InfoTech Spotlight's Homepage ]